It therefore remains to be seen whether CPI/VEGF combinations are efficacious in diseases such as ovarian cancer and MSS colorectal cancer that are angiogenic but often lack markers of preexisting immunity and respond poorly to PD-(L)1 antibody monotherapy. This evidence concerns the gene CD274 and colorectal cancer.